Viking Therapeutics (NASDAQ:VKTX – Get a review) had its price target reduced by investment analysts Roth Capital from $20.00 to $15.00 in a research report released Thursday, reports The Fly.
Several other research analysts have also recently weighed in on the stock. StockNews.com took over coverage of Viking Therapeutics shares in a Thursday, March 31 report. They issued a “sell” rating for the company. Zacks Investment Research downgraded shares of Viking Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, Jan. 7. Finally, Raymond James lowered his price target on Viking Therapeutics shares from $13.00 to $10.00 and set an “outperform” rating on the stock in a Thursday, Feb. 10 research note. One financial analyst gave the stock a sell rating, one issued a hold rating and seven issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $14.31.
Viking Therapeutics shares opened Thursday at $2.20. The stock’s 50-day simple moving average is $3.04 and its two-hundred-day simple moving average is $4.28. The stock has a market capitalization of $170.22 million, a price-earnings ratio of -3.06 and a beta of 1.67. Viking Therapeutics has a fifty-two-week low of $2.19 and a fifty-two-week high of $7.20.
Viking Therapeutics (NASDAQ:VKTX – Get Rating) last reported results on Wednesday, April 27. The biotech company reported ($0.21) EPS for the quarter, missing analyst consensus estimates of ($0.20) by ($0.01). During the same period last year, the company achieved EPS of ($0.19). As a group, equity analysts expect Viking Therapeutics to post -0.86 EPS for the current year.
Hedge funds and other institutional investors have recently changed their positions in the company. Lindbrook Capital LLC increased its position in Viking Therapeutics shares by 1,062.8% during the fourth quarter. Lindbrook Capital LLC now owns 7,500 shares of the biotech company valued at $35,000 after buying an additional 6,855 shares last quarter. Point72 Hong Kong Ltd bought a new stake in shares of Viking Therapeutics during Q4, valued at around $38,000. Qube Research & Technologies Ltd purchased a new stake in shares of Viking Therapeutics during Q4, valued at approximately $51,000. Fox Run Management LLC purchased a new stake in Viking Therapeutics stock during Q4, valued at approximately $52,000. Finally, Virtu Financial LLC acquired a new stake in Viking Therapeutics in Q4 for a value of approximately $58,000. Hedge funds and other institutional investors own 46.05% of the company’s shares.
Viking Therapeutics Company Profile (Get a rating)
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing novel therapies for metabolic and endocrine disorders. The Company’s lead drug candidate is VK2809, an orally available thyroid hormone receptor beta (TRβ) tissue and subtype selective agonist, which is in Phase IIb clinical trials to treat patients with biopsy-confirmed nonalcoholic steatohepatitis, as well as NAFLD.
Get news and reviews for Viking Therapeutics Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Viking Therapeutics and related companies with MarketBeat.com’s free daily email newsletter.